Sign in
Knowstox

Fundamentals snapshot

ProKidney Corp.

PROK · NCM · Healthcare · Biotechnology

Current price

$1.13

52-week range

$0.87 - $2.88

Market cap

$451.13M

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-41,251.75x Concerning

Net cash $178.04M. Interest coverage shows how many times profit covers the interest bill.

What this company does

ProKidney Corp.

ProKidney Corp. is developing a new type of medicine, a cell therapy, to help people with serious kidney problems. Their main product, rilparencel, is a treatment made from a patient's own cells and is currently being tested in late-stage trials for advanced chronic kidney disease, particularly for those with type 2 diabetes. This matters because if approved, it could offer a new treatment option for a widespread and serious health condition where current options are limited.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $-31.64M FY2024 Q4 $-49.68M FY2025 Q1 $-30.73M FY2025 Q2 $-34.53M FY2025 Q3 $-31.79M FY2025 Q4 $-38.27M FY2026 Q1 $-45.47M FY2026 Q2 $-44.21M
Revenue —
Net income $-28.42M
Diluted EPS —
Operating cash flow $-40.37M
Free cash flow $-44.21M
Revenue —
Net income $-20.04M
Diluted EPS —
Operating cash flow $-41.68M
Free cash flow $-45.47M
Revenue —
Net income $-19.23M
Diluted EPS —
Operating cash flow $-32.51M
Free cash flow $-38.27M
Revenue —
Net income $-16.47M
Diluted EPS —
Operating cash flow $-26.60M
Free cash flow $-31.79M
Revenue —
Net income $-16.55M
Diluted EPS —
Operating cash flow $-31.42M
Free cash flow $-34.53M
Revenue —
Net income $-16.73M
Diluted EPS —
Operating cash flow $-29.59M
Free cash flow $-30.73M
Revenue —
Net income $-21.28M
Diluted EPS —
Operating cash flow $-24.17M
Free cash flow $-49.68M
Revenue —
Net income $-17.91M
Diluted EPS —
Operating cash flow $-29.24M
Free cash flow $-31.64M

Is it cheap or expensive?

Fair value — vs current price $1.13

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $178.0M - more cash than debt. Interest coverage -41251.8x.

Net debt $-178.04M
Interest coverage -41,251.75x

ProKidney Corp.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.

Healthy
Worse cushion Baseline Better cushion
PROK BASELINE ProKidney Corp.

Total debt $3.52M Interest coverage -41,251.75x This is the baseline the peer rows are being compared against.

-41,251.75x
MAZE Maze Therapeutics, Inc.

Total debt $59.64M Interest coverage -12.13x Neither company has much profit cushion over interest right now.

-12.13x
SNDX Syndax Pharmaceuticals, Inc.

Total debt $589.41M Interest coverage -8.08x Neither company has much profit cushion over interest right now.

-8.08x
TYRA Tyra Biosciences, Inc.

Total debt $5.46M Interest coverage -10.36x Neither company has much profit cushion over interest right now.

-10.36x
NKTR Nektar Therapeutics

Total debt $135.93M Interest coverage -4.99x Neither company has much profit cushion over interest right now.

-4.99x

What you should know

The case for and against PROK

1 Reward 1 Risk

Rewards

  • Revenue grew 1075.0% last year.

Risks

  • Return on equity was -59.0% last year — the company lost money on shareholders' equity.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-1.86x
P/B
-0.26x
P/S
551.51x
EV/EBITDA
-6.83x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
100.0%
Operating margin
-21,664.5%
Net margin
0.0%
ROE
-59.0%
ROA
-35.7%

Health

Liquidity and balance-sheet strength

Debt / equity
0.02x
Current ratio
8.36x
Quick ratio
8.04x
Total debt
$3.52M
Total cash
$181.56M

Growth

How the business has been compounding

Revenue TTM
$818.00K
Revenue 5Y CAGR
—
EPS TTM
-0.55
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-141.17M
Free CF TTM
$-135.31M
FCF margin
-16,541.9%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
—
Last ex-div date
—